Old Web
English
Sign In
Acemap
>
authorDetail
>
Christopher Jones
Christopher Jones
Merck & Co.
Migraine
Medicine
Anesthesia
Clinical trial
Ubrogepant
3
Papers
91
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase 2b Clinical Trials of Ubrogepant for Migraine Treatment
2019
Clinical and Translational Science
Chi-Chung Li
Tiffini Voss
Ken Kowalski
Bei Yang
Huub-Jan Kleijn
Christopher Jones
Rolien Bosch
David Michelson
Matthew DeAngelis
Yang Xu
Iris Xie
Prajakti A. Kothare
Show All
Source
Cite
Save
Citations (2)
Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling
2018
The Journal of Clinical Pharmacology
Chi‐Chung Li
Marissa Dockendorf
Ken Kowalski
Bei Yang
Yang Xu
Iris Xie
Huub-Jan Kleijn
Rolien Bosch
Christopher Jones
Bob Thornton
Eugene E. Marcantonio
Tiffini Voss
Kevin P. Bateman
Prajakti A. Kothare
Show All
Source
Cite
Save
Citations (22)
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
2011
Headache
Kathryn M. Connor
Sheena K. Aurora
Tom Loeys
Messoud Ashina
Christopher Jones
Hilde Giezek
Rachid Massaad
Angela Williams-Diaz
Christopher Lines
Tony W. Ho
Show All
Source
Cite
Save
Citations (67)
1